Suppr超能文献

二十年来生物药剂学分类系统后选择溶解度和溶出介质的演变。

Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System.

机构信息

Faculty of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil.

United States Pharmacopeial Convention, Rockville, MD, USA.

出版信息

AAPS J. 2017 Jul;19(4):989-1001. doi: 10.1208/s12248-017-0085-5. Epub 2017 May 17.

Abstract

The introduction of the biopharmaceutics drug classification system (Biopharmaceutics Classification System (BCS)), in 1995, provided a simple way to describe the biopharmaceutics behavior of a drug. Solubility and permeability are among the major parameters, which determine the fraction dose absorbed of a drug substance and consequently its chances to be bioavailable. The purpose of this review is to summarize the evolution of the media used for determining solubility and dissolution and how this can be used in modern drug development. Over the years, physiologically adapted media and buffers were introduced with the intention to better predict the in vivo solubility and dissolution of drug substances. Water, buffer solutions, compendial media, micellar solubilization media, and biorelevant media are reviewed. At this time point, there is no universal medium available which can be used to predict every drug substance's solubility or a drug product's in vivo dissolution behavior. However, there have been many improvements and additions made to media to optimize their in vivo predictability; for example, the current phosphate concentrations in buffers seem to be too high to correlate with the carbonate buffer concentrations in vivo. Biorelevant media were updated to correlate them better with the composition of human intestinal fluids. The BCS was introduced into regulatory sciences as a scientific risk management tool to waive bioequivalence studies under certain conditions. Today's different guidance documents define the dose-solubility ratio differently. As shown for amoxicillin, this can cause more confusion than certainty for globally operating companies. Harmonization of BCS guidelines is highly desirable.

摘要

生物药剂学药物分类系统(BCS)于 1995 年推出,为描述药物的生物药剂学行为提供了一种简单的方法。溶解度和渗透性是决定药物吸收分数的主要参数之一,进而影响其生物利用度。本文旨在总结用于测定溶解度和溶解度的介质的发展,以及如何将其应用于现代药物开发。多年来,人们引入了生理适应性介质和缓冲液,旨在更好地预测药物的体内溶解度和溶解度。本文综述了水、缓冲液、法定介质、胶束增溶介质和生物相关介质。目前,尚无通用的介质可用于预测每种药物的溶解度或药物产品的体内溶解行为。然而,已经对介质进行了许多改进和添加,以优化其体内预测性;例如,目前缓冲液中的磷酸盐浓度似乎过高,无法与体内的碳酸盐缓冲液浓度相关联。生物相关介质已被更新,以更好地与人类肠道液的组成相关联。BCS 作为一种科学的风险管理工具被引入监管科学,以在某些条件下免除生物等效性研究。如今,不同的指导文件对剂量-溶解度比的定义不同。如阿莫西林所示,这可能会给跨国公司带来更多的困惑而不是确定性。因此,非常需要协调 BCS 指南。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验